3d rendered abstract illustration of the DNA.
Our Work

Latham & Watkins Advises BridgeBio Pharma in US$1.25 Billion Cross-Border Funding

January 19, 2024
Firm represented the leading biotech company in the largest private capital financing so far in 2024, one of the largest private capital financings in life sciences in the last five years, and one of the largest combined senior debt and royalty transactions in the last decade.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical focused on genetic diseases and cancers, has announced a strategic investment (combination senior secured debt and royalty investment) from Blue Owl Capital (Blue Owl) and Canada Pension Plan Investment Board (CPP Investments), through a wholly owned subsidiary (CPPIB Credit) of CPPIB Credit Investments Inc., bringing in capital of up to US$1.25 billion. The transaction strengthens BridgeBio’s balance sheet for near term, major commercial launches and other strategic growth programs.

Latham & Watkins LLP represented BridgeBio in the combined transactions with a transactional team led by partners Haim Zaltzman, Jekkie Kim, and Dan Van Fleet, with associates Hai Pham, Katherine Webb, Axel Magnusson, Julia Steinberg, Jack Gillen, Billy Wu, and Patrick Chew. Advice was also provided on tax matters by partner Eric Cho, with associate Sam Yang; on specific corporate and capital markets matters by partners Reza Majtabaee-Zamani, Drew Capurro, Sarah Axtell, Christopher Clark, and Eric Rice, with associates Raul Gonzalez and Shawn Noh; on healthcare regulatory matters by partner Betty Pang and counsel Chad Jennings; on data privacy matters by partner Heather Deixler, with associate Mitch Bennett*; on ERISA matters by partner Julie Crisp; and on investment fund regulatory matters by partner Laura Ferrell, with associate Jennifer Tian; and on security/intercreditor matters by counsel Emily Leong Yu.

*Admitted to practice in New South Wales (Australia) only.